RecruitingNCT07463287

High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps


Sponsor

Shanghai East Hospital

Enrollment

100 participants

Start Date

Apr 30, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and to identify potential transcriptomic biomarkers for high-risk polyps. The main questions it aims to answer are: What are the key gene expression differences in adenomatous polyps between MASH patients and non-fatty liver individuals? Can specific high-risk transcriptional molecules in plasma and polyp tissue serve as biomarkers for MASH-related colorectal polyps? Participants already scheduled for colonoscopic polypectomy as part of their routine care will provide a small portion of their polyp tissue, residual plasma from standard blood tests, and allow use of their stored pathological slides for research; they will also be followed up every six months.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria3

  • Diagnosis of MAFLD conforms to the "Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease" (2018 Edition);
  • Male or female patients aged 18-70 years;
  • Signed informed consent form and explanation of the specific study protocol.

Exclusion Criteria3

  • Chronic liver disease due to other etiologies (alcoholic, viral, autoimmune, drug-induced, etc.), decompensated cirrhosis, primary liver cancer;
  • Underlying diseases of other vital organs (heart, kidney, lung, etc.) and bleeding disorders;
  • Individuals lacking legal capacity or with poor insight.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07463287


Related Trials